The development and widespread use of HAART has resulted in dramatic decreases in AIDS-related mortality and morbidity; however, issues with HAART - including potency, dosing frequency, tolerability, toxicity and exacerbation of co-morbidities - have prevented some patient's from being successfully treated. Fortunately, since HAART's introduction in 1996, there have been numerous ARVs developed and approved that have significantly improved on many of the problematic characteristics of HAART. With the arrival of each new ARV, clinicians have had to weigh the potential benefits and risks of changing a patient's current HAART regimen while being mindful that while many studies have demonstrated that some patients benefit from switching one or more of the ARVs in their HAART regimen, other studies have shown that these switches are not always advantageous.
This on-demand internet symposium features four nationally known HIV thought in a case-based debate style format, reviewing and discussing relevant clinical research regarding which factors should play a role in ARV switching, including patient and ARV selection, and how to achieve the benefits of ARV switching with minimal risk.
This program has been designed to help clinicians learn more about the advantages and disadvantages of various switching strategies which will improve their professional skills and enhance their ability to provide optimal patient care, which is expected to result in improved patient outcomes.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
After completing this activity, participants should be better able to:
Release Date: June 9, 2015
Expiration Date: June 9, 2016
Estimated time to complete this on-demand program: 2 hours and 45 minutes
Media: Internet
Eric S. Daar, MD
Chief, Division of HIV Medicine Vice Chair
Department of Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Joseph Eron, MD
Professor
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Eric Daar, MD
Joseph Eron, MD
Renslow Sherer, MD
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
The following PIM planner and managers:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
There are no fees for participating and receiving CME credit for this activity. During the period, June 9, 2015 through June 9, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10686. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
